De Testimonio: On the evidence for decisions about the use of therapeutic interventions

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 8, Issue 6, 2008, Pages 579-588

  Rawlins, Michael ^a,b  

^a NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Case control studies; Hierarchies of evidence; Historical controlled trials; Randomised controlled trials

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ANTICONVULSIVE AGENT; BLEOMYCIN; CISPLATIN; CYANOCOBALAMIN; DIETHYLSTILBESTROL; GANCICLOVIR; GANGLION BLOCKING AGENT; HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; INSULIN; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; ORAL CONTRACEPTIVE AGENT; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SEROTONIN UPTAKE INHIBITOR; STREPTOMYCIN; SULFONAMIDE; THYROXINE; TRYPTOPHAN; VINBLASTINE;

ACHILLES TENDINITIS; ARTICLE; BAYES THEOREM; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL STUDY; CLINICAL TRIAL; DEFIBRILLATION; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DRUG INTOXICATION; EOSINOPHILIA MYALGIA SYNDROME; EVIDENCE BASED MEDICINE; FEMALE GENITAL TRACT CANCER; HEALTH CARE SYSTEM; HEART VENTRICLE FIBRILLATION; HEIMLICH MANEUVER; HUMAN; LARYNX STENOSIS; LOBAR PNEUMONIA; LOW LEVEL LASER THERAPY; MALIGNANT HYPERTENSION; MEDICAL DECISION MAKING; MYXEDEMA; OBSERVATIONAL STUDY; PERNICIOUS ANEMIA; PROBABILITY; RANDOMIZATION; RESOURCE ALLOCATION; RETINITIS; REYE SYNDROME; SEPSIS; STEVENS JOHNSON SYNDROME; TESTIS CANCER; TOXIC EPIDERMAL NECROLYSIS; TUBERCULOUS MENINGITIS; UPPER GASTROINTESTINAL BLEEDING; VENOUS THROMBOEMBOLISM;

EID: 57849129354     PISSN: 14702118     EISSN: None     Source Type: Journal    
DOI: 10.7861/clinmedicine.8-6-579     Document Type: Article

References (71)

1. Shapin S. The scientific revolution. Chicago and London: University of Chicago Press, 1996.
2. Gower B. Scientific method: an historical and philosophical introduction. London and New York: Routledge, 1997.
3. Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ 2001;323:334-6.
4. Jadad AR, Enkin MW. Randomized controlled trials, 2nd edn. London: BMJ Books, 2007.
5. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ 2004;329:224-7.
6. Pocock SJ. Clinical trials: a practical approach. Chichester: John Wiley & Sons, 1983.
7. Altman DG, Schulz KF, Egger M et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001;134:663-94.
8. Moher D, Schulz KF, Altman DG. The CONSORT Statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 2001;134:657-62.
9. Clarke M, Hopewell S, Chalmers I. Reports of clinical trials should begin and end with up-to-date systematic reviews of other relevant evidence: a status report. J R Soc Med 2007;100:187-90.
10. Rawlins MD. De Testimonio: on the evidence for decisions about the use of therapeutic interventions. London: Royal College of Physicians, 2008.
11. Rothman K. No adjustments are needed for multiple comparisons. Epidemiology 1990;1:43-6.
12. Schulz KF, Grimes DA. Multiplicity in randomised trials II: subgroups and interim analyses. Lancet 2005;365:1657-61.
13. Montori VM, Devereaux PJ, Adhikari NKJ et al. Randomised trials stopped early for benefit: a systematic review. JAMA 2005;294:2203-9.
14. Armitage P, Berry G, Matthews JNS. Statistical methods in medical research, 4th edn. Oxford: Blackwell, 2002.
15. Pocock SJ. When not to stop clinical trials for benefit. JAMA 2005;294: 2228-30.
16. Pocock SJ, Lubsen J. More on subgroup analyses. N Engl J Med 2008;358:2076.
17. Wang R, Lagakos SW, Ware J, Hunter DJ, Drazen JM. Statistics in medicine - reporting of subgroup analyses in clinical trials. N Engl J Med 2007;357:2189-94.
18. Ashby D. Bayesian statistics in medicine: a 25 year review. Stat Med 2006;25:3589-3631.
19. Spiegelhalter DJ, Freedman LS, Parmar MKB. Bayesian approaches to randomised trials. J R Stat Soc A 1994;157:357-416.
20. Spiegelhalter DJ, Myles JP, Jones DR, Abrams KR. Bayesian methods in health technology assessment: a review. Health Technol Assess 2000; 4:1-30.
21. Feasability, safety, and efficacy of domiciliary thrombolysis by general practitioners: Grampian region early anistreplase trial. BMJ 1992;305: 548-53.
22. Pocock SJ, Speigelhalter DJ. Grampian region early anastroplase trial. BMJ 1992;305:1015.
23. Bland JM, Altman DG. Bayesians and frequentists. BMJ 1998; 317:1151.
24. Berry D, Goodman SN, Louis TA, Temple R. Introduction to Bayesian methods: floor discussion. Clin Trials 2005;2:301-4.
25. Food and Drug Administration. Guidance for the use of Bayesian statistics in medical device trials. Draft guidance. Bethesda: US Department of Health and Human Services, Food and Drug Administration, 2006.
26. Berry DA. Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysis. Clin Trials 2005;2;295-300.
27. Grieve AP. 25 years of Bayesian methods in the pharmaceutical industry: a personal, statistical bummel. Pharm Stat 2007;6:261-81.
28. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ 1996;312:1215-8.
29. Rothwell PM. External validity of randomised controlled trials: 'To whom do the benefits apply?' Lancet 2005;365:82-93.
30. Bartlett C, Doyal L, Ebrahim S et al. The causes and effects of socio-demographic exclusions from clinical trials. Health Technol Assess 2005;9:1-152.
31. Heiat A, Gross CP, Krumhplz HM. Representation of the elderly. Women, and minorities in heart failure trials. Arch Intern Med 2002;162:1682-8.
32. McAlister FA. Applying the results of systematic reviews at the bedside. In: Egger M, Davey Smith G, Altman DG (eds), Systematic reviews in health care: meta-analysis in context. London: BMJ Books, 2001.
33. Kalra L, Yu G, Perez I, Lakhani A, Donaldson N. Prospective cohort study to determine if trial efficacy of anticoagulation for stoke prevention in atrial fibrillation translates into clinical effectiveness. BMJ 2000;320:1236-9.
34. Evans SJW. Statistics: analysis and presentation of safety data. In: Talbot J, Waller P (eds). Stephen's detection of new adverse reactions, 5th edn. Chichester: John Wiley & Sons, 2004.
35. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. JAMA 1993;270:1589-95.
36. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002;360: 942-4.
37. Califf RM. Clinical trials bureaucracy: unintended consequences of well-intentioned policy. Clin Trials 2006;3:496-502.
38. Eisenstein EL, Collins R, Cracknell BS et al. Sensible approaches for reducing clinical trial costs. Clin Trials 2008;5:75-84.
39. Rochon PA, Gurwitz JH, Sykora K et al. Readers guide to critical appraisal of cohort studies: 1. Role and design. BMJ 2005;330:895-7.
40. Ioannidis JPA, Haidich A-B, Pappa M et al. Comparison of evidence of treatment effects in randomised and non-randomised studies. JAMA 2001;286:821-30.
41. Doll R, Peto R. Randomised controlled trials and retrospective controls. BMJ 1980;280:44.
42. MacMahon S, Collins R. Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. Lancet 2001;357:455-62.
43. Glasziou P, Chalmers I, Rawlins M, McCulloch P. When are randomised trials unnecessary? Picking signal from noise. BMJ 2007; 334:349-51.
44. Normand S-LT, Sykora K, Li P et al. Readers guide to critical appraisal of cohort studies: 3. Analytical strategies to reduce confounding. BMJ 2005;330:1021-3.
45. Byar DP, Schoenfield DA, Green SB et al. Design considerations for AIDS trials. N Engl J Med 1990;323:1343-8.
46. Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965;58:295-300.
47. Grady D, Rubin SM, Pettiti DB et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37.
48. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiological evidence. Prev Med 1991;20:47-63.
49. Herrington DM. Hormone replacement therapy and heart disease. Replacing dogma with data. Circulation 2003;107:2-4.
50. Petitti DB, Freedman DA. How far can epidemiologists get with statistical adjustment. Am J Epidemiol 2005;162:415-8.
51. Boston Collaborative Drug Surveillance Group. Regular aspirin intake and acute myocardial infarction. BMJ 1870;i:440-3.
52. Smithells RW, Nevin NC, Seller MJ et al. Further experience of neural tube supplementation for prevention of neural tube defects. Lancet 1983;i:1027-39.
53. Gilbert R, Salanti G, Harden M, See S. Infant sleeping position and sudden infant death syndrome: systematic review of observational studies and historical review of recommendations from 1940 to 2002. Int J Epidemiol 2005;34:874-87.
54. Rostom A, Dubé C, Lewin G et al. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for the primary prevention of colorectal cancer: a systematic review prepared for the US Preventive Services Task Force. Ann Intern Med 2007;146:376-89.
55. Academy of Medical Sciences. Identifying the environmental causes of diseases: how should we decide what to believe and when to take action. London: Academy of Medical Sciences, 2007.
56. Davey Smith G, Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol 2004;33:30-42.
57. Sørensen HT, Christensen S, Mehnert F et al. Use of biphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 2008;336:813-6.
58. Anderson HR, Ayres JG, Sturdy PM et al. Bronchodilator treatment and deaths from asthma: case-control study. BMJ 2005;330:117-24.
59. Boston Collaborative Drug Surveillance Program. Reserpine and breast cancer. Lancet 1974;2:669-71.
60. Armstrong B, Skegg D, White G, Doll R. Rauwolfia derivatives and breast cancer in hypertensive women. Lancet 1976;2:8-12.
61. Heinonen OP, Shapiro S, Tuominen L, Turunen MI. Reserpine use in relation to breast cancer. Lancet 1974;2:675-7.
62. Grossman E, Messerli FH, Goldbourt U. Antihypertensive therapy and the risk of malignancies. Eur Heart J 2001;22:1343-52.
63. Horwitz RI, Feinstein AR. Exclusion bias and the false relationship of reserpine and breast cancer. Arch Intern Med 1985;145:1873-5.
64. Canadian Task Force on the Periodic Health Examination. The periodic health examination. CMAJ 1979;121:1193-254.
65. Agency for Healthcare Research and Quality. Systems to rate the strength of scientific evidence. Rockville, MD: AHRQ, 2002.
66. Schünemann HJ, Fretheim A, Oxman AD. Improving the use of research evidence in guideline development: 9. Grading evidence and recommendations. Health Res Policy Syst 2006;4:21.
67. Hill AB. Heberden Oration 1965: reflections on the controlled trial. Ann Rheum Dis 1966;25:107-13.
68. Freemantle N, Irs A. Observational evidence for determining drug safety. BMJ 2008;338:627-8.
69. Weinstein MC, O'Brien B, Hornberger J et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPO Task Force on Good Research Practices - Modeling Studies. Value Health 2003;6:9-17.
70. Wald NJ, Morris JK. Teleoanalysis: combining data from different types of study. BMJ 2003;327:616-8.
71. King M, Nazareth I, Lampe F et al. Impact of participant and physician intervention preferences on randomised trials. JAMA 2005; 293:1089-99.